Auxilium sues Watson on testosterone gel patent
(Reuters) - Auxilium Pharmaceuticals Inc sued Watson Pharmaceuticals Inc alleging that it infringed patents related to Auxilium's testosterone gel Testim.
A unit of Watson had filed with U.S. health regulators last month for the approval of a generic version of Testim.
As a result of the lawsuit, regulatory approval of Watson's generic version will be stayed for 30 months, or until the litigation is resolved, Auxilium said.
In its suit, Auxilium alleged that Watson's gel infringed ten patents that are expected to expire between 2023 and 2025.
Auxilium had entered into a co-promotion agreement with a unit of GlaxoSmithKline on Monday to jointly sell Testim.
Shares of Auxilium, which have risen 10 percent since the company entered into the GlaxoSmithKline agreement, closed at $19.23 on Wednesday on the Nasdaq. Watson shares were at $70.71 at close on the New York Stock Exchange on Wednesday.
(Reporting by Adithya Venkatesan in Bangalore; Editing by Sreejiraj Eluvangal)
- Tweet this
- Share this
- Digg this
- UPDATE 3-Apple sells more than 10 mln new iPhones in first 3 days
- Modi to observe strict fast during maiden trip to U.S.
- Apple sells more than 10 mln new iPhones in first 3 days
- Russia's Putin looking at cooperation to fight Islamic State - agency
- India's Mars mission a step closer to success with engine test
Sierra Leone recorded 130 new cases of the Ebola virus during a three-day lockdown and it is waiting for test results on a further 39 suspected cases, Stephen Gaojia, head of the Ebola Emergency Operations Centre, said on Monday. Full Article
Allowing blood donations from gay men could help save over a million lives: U.S. study. Full Article